Search alternatives:
table 27 » table 2a, tabelle 27, table 2.1
table 21 » table 2.1, table 11, table 2a
table b » table 3, table 4

1
by Henrikson, Nora Beidler
Published 2019
Agency for Healthcare Research and Quality
...Twelve of 18 cases (66.7%) were detected at stage I or II or classified as "resectable." Pooled...

2
by Henrikson, Nora Beidler
Published 2019
Agency for Healthcare Research and Quality
...Twelve of 18 cases (66.7%) were detected at stage I or II or classified as "resectable." Pooled...

3
by Whitlock, Evelyn P., Williams, Selvi, Burda, Brittany U., Feightner, Alisha
Published 2015
Agency for Healthcare Research and Quality, U.S. Department of Health and Human Services
...When restricted to all trials of 100 mg or less, the risk tended to decrease (OR, 1.32 [95% CI...

4
by Whitlock, Evelyn P., Williams, Selvi, Burda, Brittany U., Feightner, Alisha
Published 2015
Agency for Healthcare Research and Quality, U.S. Department of Health and Human Services
...When restricted to all trials of 100 mg or less, the risk tended to decrease (OR, 1.32 [95% CI...

5
by Henrikson, Nora Beidler
Published 2023
Agency for Healthcare Research and Quality
...), and Hispanic adults with melanoma AJCC Stage I and SEER localized stages compared to White adults. In one...

6
by Boustani, Malaz
Published 2003
Agency for Healthcare Research and Quality (US)

7
by Boustani, Malaz
Published 2003
Agency for Healthcare Research and Quality (US)

8
by Patnode, Carrie D., Perdue, Leslie A., Rushkin, Megan, O'Connor, Elizabeth A.
Published 2020
Agency for Healthcare Research and Quality, U.S. Department of Health and Human Services
... of each tool has not been evaluated in more than one study and there is no evidence on the benefits...

9
by Patnode, Carrie D., Perdue, Leslie A., Rushkin, Megan, O'Connor, Elizabeth A.
Published 2020
Agency for Healthcare Research and Quality, U.S. Department of Health and Human Services
... of each tool has not been evaluated in more than one study and there is no evidence on the benefits...